Analytical Data
-
Gene name
GAGE7
- Application
-
Alternative Names
(GAGE-7)(AL4)(Cancer/testis antigen 4.7)(CT4.7)(GAGE-12I)(GAGE-7B)(GAGE-8)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O76087
-
Expression Region
1-117aa
-
Molecular Weight
18.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAGE7, part of the GAGE gene family, has garnered significant interest in cancer immunology due to its expression in various tumors while remaining largely silent in normal tissues. This unique expression pattern positions GAGE7 as a promising target for tumor immunotherapy, particularly in the development of cancer vaccines and adoptive T-cell therapies. Research has revealed that GAGE7 functions as a tumor-associated antigen, eliciting specific immune responses in patients with certain malignancies. Its ability to activate CD8+ T cells offers potential strategies for harnessing the immune system to combat cancer. Additionally, studies have indicated that GAGE7 may play a role in regulating tumor growth and progression, further underscoring its relevance in cancer biology. Given the increasing focus on personalized medicine, understanding the immunogenicity and biological functions of GAGE7 could pave the way for novel therapeutic approaches that enhance the specificity and efficacy of cancer treatments. Consequently, ongoing investigations aim to elucidate the precise mechanisms by which GAGE7 contributes to tumor immunity and its potential as a biomarker for cancer diagnosis and prognosis. This research is vital for advancing our understanding of tumor microenvironments and developing targeted therapies that exploit the immune system's natural capacity to recognize and eliminate cancer cells. As the field of immunotherapy evolves, GAGE7 stands out as a key element in the quest for effective cancer treatment strategies.
